Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.

Background: The TARGET study has been criticised for sub-optimal platelet inhibition with tirofiban. We aimed to compare a high-dose bolus regimen of tirofiban (hd-tirofiban) to standard dose of abciximab for patients undergoing percutaneous coronary intervention (PCI).

Methods: We assessed consecutive patients who received either hd-tirofiban (25 mcg/kg bolus followed by 0.